0001764013-23-000087.txt : 20230808
0001764013-23-000087.hdr.sgml : 20230808
20230808164448
ACCESSION NUMBER: 0001764013-23-000087
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230807
FILED AS OF DATE: 20230808
DATE AS OF CHANGE: 20230808
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Salzmann Peter
CENTRAL INDEX KEY: 0001796309
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38906
FILM NUMBER: 231152145
MAIL ADDRESS:
STREET 1: 320 W 37TH STREET, 3RD FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10016
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Immunovant, Inc.
CENTRAL INDEX KEY: 0001764013
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 832771572
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0331
BUSINESS ADDRESS:
STREET 1: 320 WEST 37TH STREET
CITY: NEW YORK
STATE: NY
ZIP: 10018
BUSINESS PHONE: 917-580-3099
MAIL ADDRESS:
STREET 1: 320 WEST 37TH STREET
CITY: NEW YORK
STATE: NY
ZIP: 10018
FORMER COMPANY:
FORMER CONFORMED NAME: Health Sciences Acquisitions Corp
DATE OF NAME CHANGE: 20190108
4
1
wf-form4_169152738079375.xml
FORM 4
X0508
4
2023-08-07
0
0001764013
Immunovant, Inc.
IMVT
0001796309
Salzmann Peter
C/O IMMUNOVANT, INC.
320 W 37TH STREET, 6TH FLOOR
NEW YORK
NY
10018
1
1
0
0
Chief Executive Officer
0
Common Stock
2023-08-07
4
S
0
101339
21.73
D
1129797
D
On August 3, 2021, the holder was granted 570,613 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 4, 2021, of which the remaining 356,633 of these RSUs vested on August 3, 2023. Settlement was deferred with respect to 178,317 of the vested RSUs. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of 178,316 of the RSUs and do not represent a discretionary sale by the holder.
The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $21.26 - $22.22 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.
/s/ Eva Renee Barnett, attorney-in-fact for Peter Salzmann
2023-08-08